CVRx vs Kestra Medical Technologies
CVRX and KMTS side by side, both in surgical, medical, and dental instruments and supplies. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How CVRX and KMTS compare
Kestra Medical Technologies is the larger company, worth 105 times as much as CVRx ($1.7B against $16.2M).
Kestra Medical Technologies grew revenue faster over the last twelve months (60.7% versus 7.8% for CVRx).
CVRx keeps more of each dollar of sales as profit, with a net margin of −88.3% compared with −140% at Kestra Medical Technologies.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | CVRX | KMTS |
|---|---|---|
| Size and price | ||
| Market cap | $16.2M | $1.7B |
| Share price | $0.607 | $28.64 |
| Change, 1 year | −93.6% | 6.9% |
| Change, 5 years | −95.4% | – |
| Beta (5Y) | 1.14 | 1.21 |
| Employees | 223 | 443 |
| StockData Score | ||
| Total score | 5 | 5 |
| Valuation score | 1 (better) | 0 |
| Growth score | 2 | 3 (better) |
| Performance score | 1 (better) | 0 |
| Health score | 1 | 2 (better) |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 0.3× (better) | 16.0× |
| P/B | 1.2× | – |
| FCF yield | −260% | −7.2% (better) |
| Growth | ||
| Revenue growth (TTM) | 7.8% | 60.7% (better) |
| Revenue growth, 5Y average | 56.4% | – |
| Profitability | ||
| Gross margin | 86.9% (better) | 53.9% |
| Operating margin | −81.9% (better) | −134% |
| Net margin | −88.3% (better) | −140% |
| FCF margin | −69.7% (better) | −115% |
| Return on equity | −172% | – |
| Return on invested capital | −299% | – |
| Financial health | ||
| Debt / equity | 4.24 | – |
| Interest coverage | −8.0× (better) | −19.0× |
| Current ratio | 6.80 (better) | 4.69 |
| Altman Z-score | −10.15 | 4.94 (better) |
| Piotroski F-score | 3 | 4 (better) |
| Dividends and buybacks | ||
| Buyback yield | −35.1% | – |
| Shareholder yield | −35.1% | 0.00% (better) |
| Ownership | ||
| Held by institutions | 57.4% | 98.6% |
| Held by insiders | 49.9% | 44.0% |
| Insider net buying, 12 months | $247K (better) | −$15.3M |
| Short interest, % of float | 13.6% | 12.3% |
Go deeper
- CVRX stock overview
- CVRX income statement
- CVRX valuation and score
- KMTS stock overview
- KMTS income statement
- KMTS valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.